Genmab shares hit record after cancer drug trial shows 50% lower risk of death

Bloomberg reports Genmab shares hit an all-time high after a late-stage trial showed its experimental cancer treatment cut the risk of death by 50%. Barron’s identifies the drug as petosemtamab, an experimental treatment for head and neck cancer, and says Genmab plans to engage with regulators following the trial data.